Key result
Plasma endothelial microparticles were significantly increased in patients with mitral valve disease compared with healthy subjects and impaired endothelial function in vitro.
Why the study?
Are endothelial microparticles increased in mitral valve disease and do they impair mitral valve endothelial function?
Observational (n=126)
Are endothelial microparticles increased in mitral valve disease and do they impair mitral valve endothelial function?
Endothelial microparticles are elevated in mitral valve disease and may contribute to disease progression by impairing mitral valve endothelial function via the Akt/eNOS-HSP90 pathway.
EMPs may mark endothelial dysfunction in mitral valve disease; hypothesis-generating for causality and therapeutic targeting.
Mitral valve endothelial cells are important for maintaining lifelong mitral valve integrity and function. Plasma endothelial microparticles (EMPs) increased in various pathological conditions related to activation of endothelial cells. However, whether EMPs will increase in mitral valve disease and their relationship remains unclear. Here, 81 patients with mitral valve disease and 45 healthy subjects were analyzed for the generation of EMPs by flow cytometry. Human mitral valve endothelial cells (HMVECs) were treated with EMPs. The phosphorylation of Akt and endothelial nitric oxide synthase (eNOS), the association of eNOS and heat shock protein 90 (HSP90), and the generation of nitric oxide (NO) and superoxide anion (O(2)(∙-)) were measured. EMPs were increased significantly in patients with mitral valve disease compared with those in healthy subjects. EMPs were negatively correlated with mitral valve area in patients with isolated mitral stenosis. EMPs were significantly higher in the group with severe mitral regurgitation than those in the group with mild and moderate mitral regurgitation. Furthermore, EMPs were decreased dramatically in both Akt and eNOS phosphorylation and the association of HSP90 with eNOS in HMVECs. EMPs decreased NO production but increased O(2)(∙-) generation in HMVECs. Our data demonstrated that EMPs were significantly increased in patients with mitral valve disease. The increase of EMPs can in turn impair HMVEC function by inhibiting the Akt/eNOS-HSP90 signaling pathway. These findings suggest that EMPs may be a therapeutic target for mitral valve disease.
No takes yet. Share an insight, caveat, or question.
Ci et al. (2013) conducted an observational in Mitral valve disease (n=126). Mitral valve disease vs. Healthy subjects was evaluated on Plasma endothelial microparticle (EMP) levels. Plasma endothelial microparticles were significantly increased in patients with mitral valve disease compared with healthy subjects and impaired endothelial function in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: